NexImmune, Inc.

NEXI

Explore Our Financial Data > Companies > NexImmune, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	NEXI
CIK	0001538210
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	9119 GAITHER ROAD, GAITHERSBURG, MD, 20878
Website	neximmune.com
Phone	301-825-9810
CEO	Kristi Jones
Employees	70

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$-20.62 million
Net Income	$-20.62 million
Net Income to Common	$-20.62 million
EPS	$-14.94

View All

Balance Sheet

Cash	$2.42 million
Assets	$5.86 million
Liabilities	$4.94 million
Common Equity	$696,350.00
Liabilities & Equity	$5.86 million

View All

Cash Flow Statement

Net Income	$-20.62 million
Cash From Operating Activities	$-17.61 million
Cash From Investing Activities	$569,378.00
Cash From Financing Activities	$3.14 million
Change in Cash	$-13.89 million